Zobrazeno 1 - 10
of 48
pro vyhledávání: '"Olverling A"'
Autor:
Klockar, Rickard, Olverling, Helena
BakgrundPatellaluxation är en vanlig traumatisk knäskada hos yngre och kan leda till skada på det mediala patellofemorala ligamentet (MPFL). MPFL kan rekonstrueras kirurgiskt och det verkar bli vanligare, men konsensus saknas kring postoperativ re
Externí odkaz:
http://urn.kb.se/resolve?urn=urn:nbn:se:du-38070
Autor:
Klockar, Rickard, Olverling, Helena
BakgrundPatellaluxation är en vanlig traumatisk knäskada hos yngre och kan leda till skada på det mediala patellofemorala ligamentet (MPFL). MPFL kan rekonstrueras kirurgiskt och det verkar bli vanligare, men konsensus saknas kring postoperativ re
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=dedup_wf_001::1a7aa03b1c25c5a9fb0ad3e10840adf1
http://urn.kb.se/resolve?urn=urn:nbn:se:du-38070
http://urn.kb.se/resolve?urn=urn:nbn:se:du-38070
Publikováno v:
Clinical Science. 125:433-438
Diabetic patients are often treated with an ACEi (angiotensin-converting enzyme inhibitor) or angiotensin receptor antagonist against hypertension or albuminuria. These drugs also have a positive impact on glucose tolerance, but the mechanism for thi
Autor:
Anna Olverling, Vladimer Darsalia, Åke Sjöholm, Cesare Patrone, Emilia Darlöf, Thomas Nyström, Thomas Klein, Petra Wolbert, Henrik Ortsäter
Publikováno v:
Diabetes
Type 2 diabetes is a strong risk factor for stroke. Linagliptin is a dipeptidyl peptidase-4 (DPP-4) inhibitor in clinical use against type 2 diabetes. The aim of this study was to determine the potential antistroke efficacy of linagliptin in type 2 d
Autor:
Kerstin Iverfeldt, Shiva Mansouri, Henrik Ortsäter, Nino Nozadze, Camilla Kappe, Vladimer Darsalia, Åke Sjöholm, Cesare Patrone, Nina Grankvist, Linda Tracy, Anna Olverling
Publikováno v:
Clinical Science (London, England : 1979)
Diabetes is a strong risk factor for premature and severe stroke. The GLP-1R (glucagon-like peptide-1 receptor) agonist Ex-4 (exendin-4) is a drug for the treatment of T2D (Type 2 diabetes) that may also have neuroprotective effects. The aim of the p
Autor:
Ingrid Nilsson, Anna-Lisa E. Lawrence, Anna Olverling, Linda Fredriksson, Christina Stefanitsch
Publikováno v:
Frontiers in Cellular Neuroscience
Frontiers in Cellular Neuroscience, Vol 9 (2015)
Frontiers in Cellular Neuroscience, Vol 9 (2015)
The serine protease tissue-type plasminogen activator (tPA) is used as a thrombolytic agent in the management of ischemic stroke, but concerns for hemorrhagic conversion greatly limits the number of patients that receive this treatment. It has been s
Publikováno v:
Clinical Science. 122:375-384
GLP-1 (glucagon-like peptide 1) and its mimetic exendin-4 are used against Type 2 diabetes. C-peptide has also proven promising to enhance insulin action. Since insulin secretion in vivo can be rapidly tuned by changes in islet microcirculation, we e
Autor:
Anna Olverling, Vladimer Darsalia, Cesare Patrone, Martin Larsson, Shiva Mansouri, Åke Sjöholm, David Nathanson, Thomas Klein, Thomas Nyström
Publikováno v:
Regulatory peptides.
Dipeptidyl peptidase 4 (DPP-4) inhibitors are current drugs for the treatment of type 2 diabetes (T2D) based on their main property to enhance endogenous glucagon-like peptide-1 (GLP-1) levels, thus increasing insulin secretion. However, the mechanis
Akademický článek
Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.
K zobrazení výsledku je třeba se přihlásit.
Autor:
Xin Gao, Lin Wu, Liselotte Fransson, Anna Olverling, Henrik Ortsäter, Åke Sjöholm, Camilla Kappe
Publikováno v:
Regulatory peptides. 177(1-3)
Liraglutide, an analog of glucagon-like peptide-1 (GLP-1), is an effective anti-diabetic agent with few side effects. Since native GLP-1 exerts vascular effects, we investigated changes in pancreatic islet blood flow using a non-radioactive microsphe